Drug profile

The FDA adverse-event record for Triheart Plus

12 FDA reports name Triheart Plus, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#2393 of 2,679
by report volume (all drugs)
12
adverse-event reports
8.3%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Triheart Plus ranks #2299 of 2679 by total reports (12). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#2299
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Triheart Plus has 12 reports now versus 12 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Triheart Plus changes

Signature read: 12 reports place Triheart Plus in the lower third of FDA AER volume (#2393 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
12
Total Reports
1
Deaths Reported
8.3%
Death-coded share of reports

Active Ingredients

Triheart Plus

Administration Routes

OralUnknown

Species Affected

Dog 12

Most Affected Breeds

Sheepdog - Old English (Bobtail) 3
Retriever - Labrador 1
Dachshund (unspecified) 1
Chihuahua 1
Bulldog 1
Shepherd Dog - Australian 1
Terrier - Bull - American Pit 1
Shih Tzu 1
Deutsche Dogge, Great Dane 1
Alaskan Malamute 1

Most Reported Reactions

Unable to walk 4
Vomiting 3
Walking difficulty 3
Limpness 3
Lack of efficacy (endoparasite) - heartworm 2
Seizure NOS 1
Tremor 1
Head tremor 1
INEFFECTIVE, ATOPY CONTROL 1
Tongue disorder NOS 1
Gall bladder & bile duct disorder NOS 1
Polydipsia 1

Outcome Breakdown

Ongoing
5 (41.7%)
Recovered/Normal
4 (33.3%)
Outcome Unknown
2 (16.7%)
Euthanized
1 (8.3%)

Triheart Plus: lower report volume in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Triheart Plus (#2393 of 2,679 by report volume); death-coded 8.3%. PlainBreed drug row · report volume stamp 12 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →